Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

Jaypirca is approved for CLL/SLL patients previously treated with covalent BTK inhibitors, offering a new treatment option. The BRUIN-CLL-321 trial showed Jaypirca improved progression-free survival ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Danganronpa 2: Goodbye Despair is making a comeback in the form of Danganronpa 2x2 for PC via Steam, Nintendo Switch, Switch 2, PlayStation 5, and Xbox Series X and S. Spike Chunsoft announced a ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Among younger American adults, death from chronic disease actually increased — a rarity among high-income countries, a new report shows. By Nina Agrawal Chronic diseases like heart disease, cancer and ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...

Senior Lecturer of Exercise Immunology, Faculty of Health and Medical Sciences, School of Biosciences, University of Surrey CLL starts when a type of immune cell called a B cell – normally responsible ...